An interventional study of Individually Targeted rTMS and Conventional rTMS in Liver Diseases, Alcoholic, Fatty Liver and Metabolic Syndrome, sponsored by The Affiliated Hospital of Hangzhou Normal University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by The Affiliated Hospital of Hangzhou Normal University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:
Researchers will compare three different types of stimulation:
Participants will:
74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.
This study's planned enrollment of 105 is above the median of 90 across 44 interventional studies indexed under Liver Diseases, Alcoholic.
Browse Liver Diseases, Alcoholic studies →The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Conventional rTMS
Device: Transcranial Magnetic Stimulation Sham
Device: Individually Targeted rTMS
Participants will receive individualized transcranial magnetic stimulation (TMS) based on neuroimaging-guided localization of the nucleus accumbens (NAc). After the first MRI scan, participants will be randomized by an independent researcher responsible for data analysis. The individualized stimulation coordinates will be provided to the TMS operator before treatment. Intervention will be delivered using intermittent theta-burst stimulation (iTBS): the coil will be placed tangentially to the scalp over the individualized target. Stimulation parameters: 90% resting motor threshold (RMT); bursts of 3 pulses at 50 Hz; bursts repeated at 5 Hz; a total of 1800 pulses per session; stimulation duration 570 seconds. Each participant will receive 20 sessions in total, with at least 2 treatment days per week (2 sessions/day, 4 sessions/week). MRI and clinical assessments will be repeated at mid-treatment and after treatment completion, with follow-up clinical evaluations at 1, 3, and 6 months.
Conventional rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC) using the standard 5 cm rule for scalp-based localization. Stimulation is delivered with intermittent theta-burst stimulation (iTBS) at 90% resting motor threshold (RMT), 3 pulses at 50 Hz per burst, repeated at 5 Hz, for a total of 1800 pulses per session. Each session lasts about 570 seconds. Participants complete 20 sessions over 4 weeks, with 2 sessions per day on 2 days per week.
Sham rTMS is delivered using a sham coil or low-intensity stimulation (10% RMT) to mimic the clicking sounds and scalp sensations of active rTMS without producing cortical activation. The sham sessions are matched to the active treatment in frequency, duration, and total number: 20 sessions in 4 weeks (2 sessions/day, 2 days/week, 570 seconds per session).
Percent Change in Liver Fat Content (LFC) From Baseline to End of Treatment as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)
Time frame: From baseline to the end of treatment (Week 4)
Change in Controlled Attenuation Parameter (CAP, dB/m) From Baseline as Assessed by Vibration-Controlled Transient Elastography (FibroScan® VCTE)
Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
Change in Liver Stiffness Measurement (LSM, kPa) From Baseline as Assessed by FibroScan® VCTE
Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
LFC From Baseline as Measured by MRI-PDFF
Time frame: From baseline to the end of treatment (Week 4)
Proportion of Participants Achieving ≥30% or ≥50% Reduction in LFC From Baseline
Time frame: From baseline to the end of treatment (Week 4)
Change in Serum Levels of Liver Enzymes (ALT, AST, ALP, GGT [U/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Albumin From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in International Normalized Ratio (INR) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Prothrombin Time (PT) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Total Bilirubin (TBIL) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Proportion of Participants With ALT Reduction >17 U/L From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HOMA-IR [Index]; HOMA-β [Index]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HbA1c [%]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Plasma Glucose (FPG) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Insulin From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Conventional Lipid Panel (TC, TG, HDL-C, LDL-C, non-HDL-C, VLDL-C [mmol/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Apolipoproteins (Apo A1, Apo B [g/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Lipoprotein(a) (Lp(a)) Concentration From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Free Fatty Acids (FFA) Concentration From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Weight [kg] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in BMI [kg/m²] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Circumferences (Waist, Hip) [cm] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Waist-to-Hip Ratio From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-Trait (G-FCQ-T) Total Score From Baseline
G-FCQ-T The General Food Craving Questionnaire-Trait (G-FCQ-T) is a self-reported instrument used to assess the general tendency to experience food cravings. It comprises 21 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Never") to 6 ("Always"). The total score is the sum of all item ratings, with a possible range from 21 to 126. A higher total score indicates a more severe trait propensity for food craving.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-State (G-FCQ-S) Total Score From Baseline
G-FCQ-S The General Food Craving Questionnaire-State (G-FCQ-S) is a self-reported instrument used to assess the current, momentary state of food craving. It comprises 15 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Strongly Disagree") to 6 ("Strongly Agree"). The total score is the sum of all item ratings, with a possible range from 15 to 90. A higher total score indicates a more intense current state of food craving.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Score on Visual Analogue Scale (VAS) for Subjective Food Craving From Baseline
Subjective food craving is assessed using a Visual Analogue Scale (VAS). Participants indicate their current, momentary level of food craving by marking a point on a 100-mm horizontal line. The left endpoint (0 mm) is labeled "No food craving at all," and the right endpoint (100 mm) is labeled "The most intense food craving imaginable." The score is determined by measuring the distance from the left endpoint to the participant's mark, ranging from 0 to 100. A higher score indicates a more intense subjective feeling of food craving.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Caloric intake recorded by the Mint Health App From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Use Disorders Identification Test (AUDIT) Score From Baseline
The Alcohol Use Disorders Identification Test (AUDIT) is a simple, self-reported screening tool developed by the World Health Organization (WHO) to identify hazardous and harmful patterns of alcohol consumption. The questionnaire consists of 10 items. The first 8 items are scored on a scale from 0 to 4. Items 9 and 10 are scored 0, 2, or 4. The total score is the sum of all item ratings, with a possible range from 0 to 40. A higher total score indicates a greater likelihood of hazardous and harmful alcohol use, as well as possible alcohol dependence.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Penn Alcohol Craving Scale (PACS) Score From Baseline
The Penn Alcohol Craving Scale (PACS) is a self-reported questionnaire designed to measure the intensity of an individual's craving for alcohol over the past week. The scale consists of 5 items assessing the frequency, duration, and intensity of craving, the ability to resist drinking, and the overall rating of craving. Each item is rated on a 6-point scale from 0 to 6, with varying verbal anchors for each item (e.g., "Never" to "Nearly All the Time"). The total score is the sum of all 5 item ratings, with a possible range from 0 to 30. A higher total score indicates a more severe level of subjective alcohol craving.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Consumption Assessed by the Timeline Followback (TLFB) Method From Baseline
Alcohol consumption is assessed using the Timeline Followback (TLFB) method, a structured interview that provides a quantitative estimate of an individual's daily drinking. Using a calendar to aid recall, participants retrospectively report their daily alcohol consumption over a specified period (e.g., the past 30 days). The data is used to calculate key metrics such as the number of drinking days, the number of heavy drinking days, and the average number of standard drinks consumed per day or per week. A higher value indicates a greater level of alcohol consumption.
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Resting-State Functional Connectivity (rs-FC) Measured by fMRI
Resting-state functional connectivity (rs-FC) will be assessed using functional magnetic resonance imaging (fMRI). This measures the temporal correlation of spontaneous brain activity between different neural regions, forming functional networks (e.g., Default Mode Network, Executive Control Network). The strength of connectivity is represented by correlation coefficients (z-values). A higher absolute value indicates stronger functional connectivity.
Time frame: From baseline to mid-treatment (Week 2) and end of treatment (Week 4)
Amplitude of Low-Frequency Fluctuations (ALFF) Measured by fMRI
The amplitude of low-frequency fluctuations (ALFF) will be calculated from resting-state fMRI data. It measures the intensity of spontaneous neural activity in specific brain regions. The value is typically presented as a normalized Z-score. A higher ALFF value indicates greater regional spontaneous neural activity.
Time frame: From baseline to mid-treatment (Week 2) and end of treatment (Week 4)
Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Hangzhou Normal University